
OrSense Noninvasive Hemoglobin Monitor Obtains FDA Approval



The innovative NBM-200MP, a noninvasive haemoglobin (Hb) and pulse oximetry monitor developed by OrSense Ltd, is the company's latest model to receive FDA clearance, joining the established NBM-200 products range.

OrSense is a leading provider of solutions for non-invasive measurements of various blood parameters, and their NBM-200MP enables specific monitoring of anaemia and hemorrhage.

Hb measurements are currently obtained via the collection of blood samples, with traditional testing methods being invasive, painful, time consuming and labor intensive.

OrSense's pioneering systems offer a novel and noninvasive alternative for reliable Hb measurements, paving the way for enhanced, pain free anaemia detection and monitoring. Hb levels can be analysed swiftly, all the while with a decreased risk of infection for the patient.

In acute conditions when measuring Hb is critical, such as in childbirth or during surgery, OrSense's noninvasive monitoring device NBM-200MP offers the possibility of continuous screening under the most stable conditions.

The fact that the company's systems are compatible with a range of clinical settings in addition to hospitals, they are utilised in homecare, women's health, public screening and primary care.

Lior Maayan, CEO of OrSense, explains that over 400 million haemoglobin level laboratory tests are conducted each year in the US alone, yet testing for this crucial parameter continues to be expensive, labor intensive and invasive. He believes that the company's noninvasive haemoglobin monitor is transforming the management of chronic as well as acute anaemia, and is excited about the US FDA approval. After having already been awarded the CE Mark and China FDA approval for their NBM-200MP, OrSense is looking forward to bringing OrSense's solution to the US market.

Source: [Business Wire](#)

5 November 2013

Published on : Wed, 6 Nov 2013